Application of New Data in B-Cell Malignancies From ASCO and EHA 2020: Waldenström Macroglobulinemia, Mantle Cell Lymphoma, Hodgkin Lymphoma, and Diffuse Large B-Cell Lymphoma

In this episode, Jennifer R. Brown, MD, PhD, and John Allan, MD, discuss recent key clinical trial results in Waldenström macroglobulinemia, mantle cell lymphoma, Hodgkin lymphoma, and DLBCL presented at the 2020 annual meetings of the American Society of Clinical Oncology (ASCO) and the European Hematology Association (EHA). Studies include:

• ASPEN: Zanubrutinib vs ibrutinib in WM
• OASIS: Ibrutinib, venetoclax, and obinutuzumab in MCL
• GHSG HD17: PET-guided therapy in HL
• KEYNOTE-024: Pembrolizumab vs brentuximab in HL
• ALEXANDER: AUTO3 in DLBCL

Presenters:

Jennifer R. Brown, MD, PhD
Associate Professor of Medicine
Department of Hematologic Malignancies
Dana-Farber Cancer Institute
Harvard Medical School
Director, CLL Center
Department of Medical Oncology
Dana-Farber Cancer Institute
Boston, Massachusetts

John Allan, MD
Assistant Professor of Medicine
Division of Hematology and Medical Oncology
Weill Cornell Medicine
New York, New York

Content based on an online CME program supported by an educational grant from AstraZeneca.

Link to full program: https://bit.ly/3aSfekM